Umoja wa Ulaya - Kiholanzi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals voor felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Umoja wa Ulaya - Kiholanzi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. onsets van immuniteit zijn aangetoond een week na de primaire vaccinatiekuur voor rhinotracheitis, calicivirus, chlamydophila felis en panleucopenie componenten. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Umoja wa Ulaya - Kiholanzi - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals voor felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Uholanzi - Kiholanzi - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

kernfarm b.v. - !!zie spc; geÏnactiveerd actinobacillus pleuropneumoniae, serotype 2; geÏnactiveerd actinobacillus pleuropneumoniae, serotype 2 stam sz ii; geÏnactiveerd actinobacillus pleuropneumoniae, serotype 9 - emulsie voor injectie - actinobacillus/haemophilus vaccine - varkens

Umoja wa Ulaya - Kiholanzi - EMA (European Medicines Agency)

vbi vaccines b.v. - hepatitis b-oppervlakte-antigeen - hepatitis b - vaccins - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Uholanzi - Kiholanzi - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

accord healthcare b.v. - carprofen - oplossing voor injectie - carprofen 50 mg/ml, - carprofen - runderen

Uholanzi - Kiholanzi - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

dopharma research b.v. - amoxicilline 0-water - poeder voor gebruik in drinkwater - amoxicilline 0-water 697 mg/g, - amoxicillin - eenden; kalkoenen; kippen

Ubelgiji - Kiholanzi - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intervet international - levend boviene herpesvirus type 1 (bhv1) 5,7 log10 tcid50/dose - lyofilisaat en oplosmiddel voor suspensie voor nasaal gebruik; lyofilisaat en oplosmiddel voor suspensie voor injectie - levend boviene herpesvirus type 1 (bhv1) - bovine viral diarrhea (bvd) - rund

Ubelgiji - Kiholanzi - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intervet international - levend boviene herpesvirus type 1 (bhv1) 5,7 log10 tcid50/dose - lyofilisaat en oplosmiddel voor suspensie voor nasaal gebruik; lyofilisaat en oplosmiddel voor suspensie voor injectie - levend boviene herpesvirus type 1 (bhv1) - bovine viral diarrhea (bvd) - rund

Ubelgiji - Kiholanzi - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intervet international b.v. - levend, geattenueerd, boviene parainfluenza-3-virus ; levend, geattenueerd, boviene respiratory syncytial-virus (brsv) - neusspray, lyofilisaat en oplosmiddel voor suspensie - gemodificeerd levend boviene parainfluenza-3-virus; boviene respiratory syncytial-virus (brsv) - bovine respiratory syncytial virus + bovine parainfluenza virus - rund